Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety and Tolerability of TL-925 Ophthalmic Emulsion 0.1% in Subjects With Moderate to Severe Dry Eye Disease

NCT05745064 is registered in ClinicalTrials.gov with Telios Pharma, Inc. as lead sponsor.

NCT NCT05745064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05745064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety and Tolerability of TL-925 Ophthalmic Emulsion 0.1% in Subjects With Moderate to Severe Dry Eye Disease
Lead sponsor
Telios Pharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 27, 2023
Completion date
July 11, 2023
Enrollment
107 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye disease